Literature DB >> 25550572

Usefulness of duloxetine for Paclitaxel-induced peripheral neuropathy treatment in gynecological cancer patients.

Akiko Otake1, Kiyoshi Yoshino2, Yutaka Ueda1, Kenjiro Sawada1, Seiji Mabuchi1, Toshihiro Kimura1, Eiji Kobayashi1, Aki Isobe1, Tomomi Egawa-Takata1, Shinya Matsuzaki1, Masami Fujita3, Tadashi Kimura1.   

Abstract

AIM: The present study aimed at evaluating the usefulness and adverse effects of duloxetine treatment for paclitaxel-induced peripheral neuropathy in gynecological cancer patients. PATIENTS AND METHODS: Medical records of gynecological cancer patients treated with duloxetine were retrospectively studied to evaluate the drug's efficacy for paclitaxel-induced peripheral neuropathy.
RESULTS: RESULTS from 25 patients showed that an improved response was observed in 14 (56%). By univariate and multivariate analysis, the patient's age, tumor origin, regimen of chemotherapy, accumulated doses of paclitaxel or carboplatin, previous medication, maintenance dosage and timing of treatment with duloxetine were found not to be associated with the effectiveness of duloxetine treatment. Adverse effects with duloxetine were mild and well-tolerated.
CONCLUSION: As an option, duloxetine can be effectively used for paclitaxel-induced peripheral neuropathy in patients with gynecological cancers, irrespective of patients' age, origin of the tumor, regimen of chemotherapy, or previous medication. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  CIPN; duloxetine; gynecologic cancer; neuropathy; paclitaxel

Mesh:

Substances:

Year:  2015        PMID: 25550572

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Predictors of the usefulness of duloxetine for chemotherapy-induced peripheral neuropathy.

Authors:  Yuko Kanbayashi; Megumi Inagaki; Hiroshi Ueno; Toyoshi Hosokawa
Journal:  Med Oncol       Date:  2017-07-07       Impact factor: 3.064

2.  Cancer and treatment-related symptoms are associated with mobility disability in women with ovarian cancer: A cross-sectional study.

Authors:  Grace Campbell; Teresa Hagan; Stephanie Gilbertson-White; Martin Houze; Heidi Donovan
Journal:  Gynecol Oncol       Date:  2016-09-18       Impact factor: 5.482

3.  Risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: A retrospective study in Japan.

Authors:  Shiori Hiramoto; Hajime Asano; Tomoyoshi Miyamoto; Manabu Takegami; Atsufumi Kawabata
Journal:  PLoS One       Date:  2021-12-31       Impact factor: 3.240

4.  Efficacy of Siriraj, in-house-developed, frozen gloves for cold therapy reduction of chemotherapy-induced peripheral neuropathy in gynecological cancer patients: randomized controlled trial.

Authors:  Phreerakan Chitkumarn; Tharinee Rahong; Vuthinun Achariyapota
Journal:  Support Care Cancer       Date:  2022-02-11       Impact factor: 3.359

5.  Effect of serotonin-norepinephrine reuptake inhibitors for patients with chemotherapy-induced painful peripheral neuropathy: A meta-analysis.

Authors:  Soo Youn Song; Young Bok Ko; Hyeun Kim; Geon Woo Lee; Jung Bo Yang; Ha Kyun Chang; Sang Mi Kwak; Jaeyun Jung; Siyeo Lee; Sun Yeul Lee; Heon Jong Yoo
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.